Diagnostic Performance of Donor‐derived Cell‐free DNA Combined With Immune Activation Markers for Detecting Acute Rejection After Liver Transplantation
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70701 ↗At a glance
Journal article in Clinical Transplantation, 2026. Written by Xuechun Zhao and 6 co-authors. Institution: Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, PR…. Major MEDLINE topics: Liver Transplantation, Graft Rejection, Cell-Free Nucleic Acids, Biomarkers. 21 references.
Abstract (original language)
Background
Accurate differentiation of acute rejection (AR) from other causes of graft dysfunction after liver transplantation remains challenging in real‐world clinical practice. Although donor‐derived cell‐free DNA (dd‐cfDNA) has emerged as a promising non‐invasive biomarker of graft injury, its specificity may be limited in clinically suspected rejection due to concurrent inflammatory and non‐rejection‐related graft injuries. Immune activation markers may provide complementary information by reflecting ongoing alloimmune responses.
Methods
In this prospective diagnostic study, we enrolled liver transplant recipients presenting with graft dysfunction and classified them as AR or non‐rejection based on biopsy. Plasma dd‐cfDNA levels and peripheral immune activation markers, including interleukin‐2 receptor (IL‐2R) and activated T‐cell subsets, were measured. Diagnostic performance was evaluated using receiver operating characteristic analysis and multivariable models.
Results
A total of 33 patients were included, comprising 18 with biopsy‐proven AR and 15 with non‐rejection graft dysfunction. dd‐cfDNA levels were significantly higher in AR patients. Selected immune activation markers demonstrated complementary diagnostic characteristics. A simplified combined model integrating dd‐cfDNA percentage with activated T‐cell subsets achieved improved discrimination compared with individual markers. Decision curve analysis indicated a higher net clinical benefit across a range of threshold probabilities.
Conclusion
Integration of dd‐cfDNA with immune activation markers provides a complementary non‐invasive strategy for evaluating acute rejection in liver transplant recipients with clinically suspected graft dysfunction. This approach may improve real‐world diagnostic assessment and assist clinical decision‐making while reducing unnecessary liver biopsies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, PR China.
- Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, Hubei Province, PR China.
- NHC Key Laboratory of Organ Transplantation, Wuhan, Hubei Province, PR China.
- Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei Province, PR China.
- Hubei Provincial Clinical Research Center for Organ Transplantation, Wuhan, Hubei Province, PR China.
Cite
APA
Zhao, X., Yang, B., Jiang, H., Zhao, Y., Wei, L., Chen, Z., & Chen, D. (2026). Diagnostic Performance of Donor‐derived Cell‐free DNA Combined With Immune Activation Markers for Detecting Acute Rejection After Liver Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70701
Vancouver
Zhao X, Yang B, Jiang H, Zhao Y, Wei L, Chen Z, et al. Diagnostic Performance of Donor‐derived Cell‐free DNA Combined With Immune Activation Markers for Detecting Acute Rejection After Liver Transplantation. Clinical Transplantation. 2026. doi:10.1111/ctr.70701
BibTeX
@article{Zhao2026,
author = {Zhao, Xuechun and Yang, Bo and Jiang, Hongmei and Zhao, Yuanyuan and Wei, Lai and Chen, Zhishui and Chen, Dong},
title = {Diagnostic Performance of Donor‐derived Cell‐free DNA Combined With Immune Activation Markers for Detecting Acute Rejection After Liver Transplantation},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70701}
}
EUVIMED